Green Alpha Advisors LLC Makes New $1.09 Million Investment in Tempus AI, Inc. (NASDAQ:TEM)

by · The Markets Daily

Green Alpha Advisors LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 32,283 shares of the company’s stock, valued at approximately $1,090,000.

A number of other hedge funds have also recently modified their holdings of TEM. First Horizon Advisors Inc. acquired a new position in Tempus AI in the third quarter valued at approximately $30,000. Vestor Capital LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at approximately $153,000. Stifel Financial Corp acquired a new position in shares of Tempus AI in the 3rd quarter valued at $218,000. Sandia Investment Management LP purchased a new stake in Tempus AI during the second quarter worth $136,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Tempus AI during the third quarter valued at $258,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Insider Transactions at Tempus AI

In related news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the transaction, the chief operating officer now owns 982,442 shares in the company, valued at approximately $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 865,041 shares of company stock valued at $35,917,673.

Analysts Set New Price Targets

TEM has been the subject of a number of analyst reports. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America upped their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Guggenheim started coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Wolfe Research initiated coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Loop Capital lifted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.00.

View Our Latest Report on Tempus AI

Tempus AI Stock Performance

Shares of TEM opened at $37.52 on Monday. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $79.49. The firm’s fifty day moving average is $48.28 and its two-hundred day moving average is $47.27. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Tempus AI Company Profile

(Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Featured Stories

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).